Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
about
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Gemcitabine plus sirolimus for ...... or Research on Sarcoma (GEIS).
@en
Gemcitabine plus sirolimus for ...... or Research on Sarcoma (GEIS).
@nl
type
label
Gemcitabine plus sirolimus for ...... or Research on Sarcoma (GEIS).
@en
Gemcitabine plus sirolimus for ...... or Research on Sarcoma (GEIS).
@nl
prefLabel
Gemcitabine plus sirolimus for ...... or Research on Sarcoma (GEIS).
@en
Gemcitabine plus sirolimus for ...... or Research on Sarcoma (GEIS).
@nl
P2093
P2860
P356
P1433
P1476
Gemcitabine plus sirolimus for ...... or Research on Sarcoma (GEIS).
@en
P2093
A Carranza
A Gutierrez
A Lopez-Pousa
C Valverde
D Marcilla
J Martin-Broto
P2860
P304
P356
10.1093/ANNONC/MDX536
P577
2017-09-25T00:00:00Z